Covered recipient · General Payments record
MICHELLE SON
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2023–2024
$2,464.98
- Reported across 80 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,901.98 | 62 |
| Education | $99.95 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $213.53 | 2 |
| Incyte Corporation | $153.23 | 3 |
| EISAI INC. | $147.38 | 4 |
| Janssen Biotech, Inc. | $146.75 | 5 |
| MY01 Inc. | $144.79 | 1 |
| SOBI, INC | $129.53 | 2 |
| PFIZER INC. | $128.30 | 6 |
| ABBVIE INC. | $117.45 | 1 |
| SpringWorks Therapeutics, Inc. | $89.28 | 3 |
| BeiGene USA, Inc. | $88.11 | 4 |
| Regeneron Healthcare Solutions, Inc. | $62.94 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $57.58 | 3 |
| Acerta Pharma LLC | $57.38 | 3 |
| Lilly USA, LLC | $53.96 | 2 |
| Amgen Inc. | $49.64 | 3 |
| Coherus Biosciences Inc. | $41.75 | 2 |
| GlaxoSmithKline, LLC. | $32.44 | 1 |
| Genentech USA, Inc. | $25.58 | 1 |
| Celgene Corporation | $24.80 | 1 |
| PharmaEssentia USA Corporation | $24.20 | 1 |
| Astellas Pharma US Inc | $23.08 | 1 |
| Invivyd Inc | $22.77 | 1 |
| SERVIER PHARMACEUTICALS LLC | $22.59 | 1 |
| Genmab U.S., Inc. | $21.77 | 1 |
| Aadi Bioscience, Inc. | $21.23 | 2 |
| Fennec Pharmaceuticals, Inc. | $19.46 | 1 |
| Agios Pharmaceuticals, Inc. | $18.65 | 1 |
| Exelixis Inc. | $17.82 | 1 |
| Pharmacosmos Therapeutics Inc. | $16.78 | 1 |
| E.R. Squibb & Sons, L.L.C. | $15.22 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $13.94 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (63)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.